Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Effect of FP-025, a MMP-12 Inhibitor, on Allergen-induced Airway Responses, Airway Inflammation and Aspects of Airway Remodeling in Subjects With Mild Eosinophilic House Dust Mite (HDM)-Allergic Asthma (HDM)-Allergic Asthma

Next Previous
Trial Profile

The Effect of FP-025, a MMP-12 Inhibitor, on Allergen-induced Airway Responses, Airway Inflammation and Aspects of Airway Remodeling in Subjects With Mild Eosinophilic House Dust Mite (HDM)-Allergic Asthma (HDM)-Allergic Asthma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Jun 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs FP 025 (Primary)
  • Indications Allergic asthma; Asthma
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Foresee Pharmaceuticals

Most Recent Events

  • 22 May 2024 Results presented at the 120th International Conference of the American Thoracic Society
  • 29 Apr 2024 According to a Foresee Pharmaceuticals media release, data from this trial will be presented at 2024 American Thoracic Society (ATS) International Conference
  • 11 Sep 2023 According to Foresee Pharmaceuticals Media Release, data from this study were presented at the European Respiratory Society (ERS) International Congress 2023

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top